Precision BioSciences to Present Further PBGENE-HBV Data Showing cccDNA Elimination at AASLD 2026

What happened

Precision BioSciences announced it will present late-breaking Phase 1 data from its PBGENE-HBV program at AASLD 2026, further demonstrating cccDNA elimination and potential to drive a viral cure. This builds on earlier ELIMINATE-B results that showed dose-dependent HBsAg reductions and molecular evidence of viral DNA editing. Despite a strong cash position relative to its market cap, the stock has been weighed down by dilution concerns and capital constraints. If the new data confirms broader cccDNA elimination with clean safety, it would significantly de-risk the HBV program and validate the ARCUS platform. However, investors should scrutinize the full dataset, including safety and durability, before extrapolating to a functional cure.

Implication

The HBV program's ability to eliminate cccDNA is the linchpin of the investment thesis, and credible data could attract partnership interest and reduce reliance on dilutive financing. If the presentation confirms durable viral DNA editing with no dose-limiting toxicities, the stock could move toward the bull scenario of $6.80, though current cash constraints and Baby Shelf limitations may temper upside. Conversely, if the data raises safety concerns or fails to show broader editing across patients, the stock could retreat toward the bear case of $2.40. Investors should also monitor the DMD program, which is expected to dose its first patient in early 2026, as a second catalyst. Near-term trading will likely be driven by the details of the AASLD presentation and management's commentary on the path to a registrational trial.

Thesis delta

The new data further supports the HBV mechanism, increasing confidence in the program's potential to achieve a functional cure. The investment thesis remains intact but is now more dependent on the durability and breadth of cccDNA elimination demonstrated at AASLD. The balance sheet and dilution dynamics continue to be a key risk factor that could cap valuation despite positive clinical progress.